(Q38407722)

2 September 2017

1 reference

title

Ritonavir-boosted protease inhibitor based therapy: a new strategy in chronic hepatitis C therapy (English)

1 reference

2 September 2017

1 reference

1 reference

1 reference

2

K Rajender Reddy

1 reference

2 September 2017

Samuel W Brayer

1

1 reference

2 September 2017

6 April 2015

1 reference

Expert Review of Gastroenterology & Hepatology

2 September 2017

1 reference

2 September 2017

9

1 reference

2 September 2017

5

1 reference

2 September 2017

547-558

1 reference

Evolving epidemiology of hepatitis C virus in the United States

2 September 2017

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1032938

Treatment of hepatitis C: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1032938

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1032938

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1032938

Sofosbuvir and ribavirin in HCV genotypes 2 and 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1032938

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1032938

All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1032938

Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1032938

ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1032938

Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1032938

Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1032938

A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1032938

Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1032938

Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1032938

Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1032938

Replication of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1032938

Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1032938

The role of resistance in HCV treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1032938

Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1032938

Principles and practice of HIV-protease inhibitor pharmacoenhancement

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1032938

Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1032938

Low-dose ritonavir for protease inhibitor pharmacokinetic enhancement

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1032938

Forthcoming challenges in the management of direct-acting antiviral agents (DAAs) for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1032938

Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1032938

P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1032938

Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1032938

Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC transporter-overexpressing cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1032938

Recognition of sulfonylurea receptor (ABCC8/9) ligands by the multidrug resistance transporter P-glycoprotein (ABCB1): functional similarities based on common structural features between two multispecific ABC proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1032938

Drugs as P-glycoprotein substrates, inhibitors, and inducers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1032938

Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1032938

Preclinical Pharmacokinetics and In Vitro Metabolism of Asunaprevir (BMS-650032), a Potent Hepatitis C Virus NS3 Protease Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1032938

Hepatitis C virus-related cirrhosis is a major determinant of the expression levels of hepatic drug transporters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1032938

Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1032938

Pharmacokinetic enhancement of the hepatitis C virus protease inhibitors VX-950 and SCH 503034 by co-dosing with ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1032938

Simeprevir for the treatment of hepatitis C and HIV/hepatitis C co-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1032938

A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1032938

Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1032938

Pharmacokinetics of fosamprenavir plus ritonavir in human immunodeficiency virus type 1-infected adult subjects with hepatic impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1032938

Quantitative testing of liver function in relation to fibrosis in patients with chronic hepatitis B and C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1032938

Exploratory study of oral combination antiviral therapy for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1032938

Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1032938

Boceprevir for previously treated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1032938

Telaprevir for retreatment of HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1032938

ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1032938

Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1032938

Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1032938

Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1032938

An interferon-free antiviral regimen for HCV after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1032938

10.1586/17474124.2015.1032938

21 January 2018

Identifiers

DOI

1 reference

2 September 2017

1 reference

PubMed ID

25846301